NCT06925919View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011

PHASE1RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

April 2, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions

Rift Valley Fever

Interventions

DRUG

IDB-011 dose level 1

IDB-774 + IDB-898

DRUG

IDB-011 dose level 2

IDB-774 + IDB-898

DRUG

IDB-011 dose level 3

IDB-774 + IDB-898

DRUG

IDB-011 dose level 4

IDB-774 + IDB-898

DRUG

IDB-011 dose level 5

IDB-774 + IDB-898

OTHER

Placebo

Normal saline

Trial Locations (1)

90630

RECRUITING

Altasciences Clinical Los Angeles, Cypress

Sponsors

Lead Sponsor

IDBiologics, Inc.

All Listed Sponsors

collaborator

Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies

OTHER_GOV

lead

IDBiologics, Inc.

INDUSTRY

NCT06925919 - Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011 | Biotech Hunter | Biotech Hunter